Burroughs Wellcome Navelbine

Executive Summary

Treatment IND for vinorelbine in ambulatory patients with unresectable non-small cell lung cancer who have not had prior chemotherapy begins May 4. An estimated 20% of the 500 patients who are diagnosed in the U.S. with lung cancer daily could be eligible to receive the drug. Approval of Navelbine has been recommended by FDA's Oncology Drugs Advisory Cmte. ("The Pink Sheet" Dec. 20, 1993, p. 10). An NDA for the treatment of advanced breast cancer was submitted on March 31, and Phase II trials for ovarian and prostate cancer are under way